Clinical Trial Update: Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating safety and efficacy of HDR prostate brachytherapy doses of 21 Gy, 23 Gy, and 25 Gy in Phase 1/2. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Washington University School of Medicine | Conditions: Prostate Cancer, Prostate Neoplasm | Phase 1, Phase 2 | Status: RECRUITING